ChrisM
2021-06-18

$Orphazyme A/S(ORPH)$Just a bit of warning as most traders here came from wsb or something:

 The FDA rejected their primary drug candidate. This is why the stock is down so much pre-market as it's a death sentence for small biotech firms in the short to medium term.

Company will only recover either with:

1. New data to reverse FDA decision

2. New drugs

3. Some weird retail push, but please know that everyone will sell this besides crazy wsb people I guess.


Point 1 and 2 can take a long time. So till then this can be close to dead.

Please do research, biotech companies live or die by trial results and FDA decisions, this is not just a dip.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Gloriana
    2021-06-24
    Gloriana
    The rejection was from last week, the $77 was For that. The new rally has nothing to do with the expectation for the approva…. so WhaT you are talking about is an outdated info
    • ChrisM
      my post is from last week..... check dates next time.
  • tzyan35
    2021-06-23
    tzyan35
    did not age well
    • ChrisM
      dead cat bounce. am not touching this stuff. my above still stands. it's nowhere near recovered
  • boredpanda
    2021-06-18
    boredpanda
    prime time to short then
Leave a comment
5